May 16, 2021
Ultrasound-based renal denervation (Paradise; ReCor Medical) significantly lowers systolic blood pressure when compared with a sham procedure in patients with resistant hypertension treated on a background of antihypertensive therapy, the RADIANCE-HTN TRIO shows.
Renal denervation reduced daytime ambulatory systolic blood pressure by 8.0 mm Hg compared with a 3.0-mm Hg reduction observed in patients treated with the sham procedure, a median between-group difference of 4.5 mm Hg (
P = 0.02). Additionally, there were significant between-group reductions in 24-hour ambulatory systolic blood pressure, nighttime ambulatory systolic blood pressure, and office- and home-based systolic blood pressure.
“I don’t want to be perceived as overselling anything, but sham-controlled controls are great for determining if there is an effect or not,” senior investigator Ajay Kirtane, MD (NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY), told TCT
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. Study initiation is expected in the second quarter of 2021.